A Study to See if we Can Predict How Your Liver Tumor or Liver Metastases Will Respond to Trans-Arterial Embolization (TAE)
| Status: | Withdrawn |
|---|---|
| Conditions: | Liver Cancer, Cancer, Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 2/1/2017 |
| Start Date: | April 2016 |
A PILOT STUDY TO IDENTIFY MOLECULAR PREDICTORS OF SENSITIVITY AND RESISTANCE TO TRANS-ARTERIAL EMBOLIZATION OF PRIMARY LIVER TUMORS AND LIVER METASTASES
The purpose of this study is to see if certain genes the tumor can help predict how the
tumor will respond to Trans-Arterial Embolization (TAE). A gene is the basic physical and
functional unit of heredity. Genes are made up of DNA; DNA (deoxyribonucleic acid) is the
hereditary material in humans. Identifying a gene that can predict how liver tumors will
respond to TAE will also help to determine if adjuvant therapy will be needed after TAE.
tumor will respond to Trans-Arterial Embolization (TAE). A gene is the basic physical and
functional unit of heredity. Genes are made up of DNA; DNA (deoxyribonucleic acid) is the
hereditary material in humans. Identifying a gene that can predict how liver tumors will
respond to TAE will also help to determine if adjuvant therapy will be needed after TAE.
Inclusion Criteria:
- Histopathologic evidence of primary liver cancer or liver metastases
- Indication of TAE for the treatment of liver tumor
- Age ≥ 18 years
- Available tissue with adequate tissue for analysis, verified by a pathologist
Exclusion Criteria:
- History of a second active malignancy with evidence of metastatic disease
We found this trial at
1
site
1275 York Ave
New York, New York 10021
New York, New York 10021
(212) 639-2000
Principal Investigator: Etay Ziv, MD, PhD
Phone: 212-639-3312
Memorial Sloan Kettering Cancer Center Memorial Sloan Kettering Cancer Center — the world's oldest and...
Click here to add this to my saved trials
